Projects of SRDA (Slovak Research and Development Agency)
Cytokine profiling together with carbonic anhydrase IX immunotargeting as a promising tool in diagnostics and treatment of pancreatic cancer. Project code: APVV-20-0480, PI: Eliška Švastová. Duration: 07/2021-06/2025.
Nanomedical approach to fight pancreatic cancer via targeting tumor-associated carbonic anhydrase IX. Project code: APVV-20-0485, PI: Lucia Csaderova. Duration: 07/2021-06/2025.
Development of unique TiMg composite dental implant. Project code: APVV-20-0417. Collaborative project. PI in BMC: Martina Takacova. Duration: 07/2021-06/2025.
Elucidation of novel pro-metastatic functions of tumor-associated carbonic anhydrase IX and its cross-talk with proinflammatory response. Project code: APVV 14-0816. PI: Eliška Švastová. Duration: 2015-2019.
The role of CA IX in adaptation to tumor microenvironment and in resistance to anticancer therapy: molecular mechanisms and clinical implications. Project code: APVV 15-0697. PI: Silvia Pastoreková. Duration: 2016-2020.
Activity Assay of Transfer Factor, Immunostimulatory Drug from Leukocytes Extract And Its Preparation Standardization. Project code: APVV 15-0720, PI: Juraj Kopáček. Duration: 2016-2020.
Impact of comorbidity therapy on tumorigenesis and a role of the tumor microenvironment in this process. Project code: APVV 16-0343, PI: Monika Baráthová. Duration: 2017-2021.
Cell-in-cell phenomena as microevolutionary processes in cancer progression: a role for hypoxia-induced carbonic anhydrase IX. Project code: APVV 19-0098, PI: Silvia Pastoreková, Duration: 2020-2024.
Projects of VEGA (Scientific Grant Agency of the Ministry of Education, of the SR and the Slovak Academy of Sciences)
Effects of natural polyphenol and nonsteroidal anti-inflammatory drug combination therapy on the tumormicroe nvironment. Project code: VEGA (2/0061/21), PI: Katarína Grossmannová. Duration: 2021-2024.
Regulation of pyruvate dehydrogenase kinase 1 activity in the control of glycolytic metabolism in hypoxic tumors. Project code: VEGA (2/0078/19), PI: Tereza Goliaš. Duration: 2019-2022.
Study of pro-metastatic functions of carbonic anhydrase IX, relationship between CA IX and mucins and hypoxic microenvironment in pancreatic cancer. Project code: VEGA (2/0105/19), PI: Eliška Švastová. Duration: 2019-2022.
Unraveling the mechanisms linking obesity and cancer progression: the interplay between adipocytes and cancer cells. Project code: VEGA (2/0076/20), PI: Martina Takáčová. Duration: 2020-2023.
Effect of combination therapy with carnosine on tumorigenesis in colorectal carcinoma models. Project code: VEGA (VEGA 2/0090/20), PI: Monika Baráthová. Duration: 2020-2023.
Carbonic anhydrase IX as one of the key components of exosomes secreted from cancer cells. Project code: VEGA (2/0074/20), PI: Miriam Zaťovičová. Duration: 2020-2023.
Collaboration projects:
Projects of The Ministry of Education, Science, Research and Sport of the Slovak Republic:
Research of humanized antibodies in targeted treatment of hypoxic tumors. Project code: (2018/14554:1-26C0), principal investigator: MABPRO a.s., PI: Jaromír Pastorek; Cooperating organization: BMC SAV, PI: Silvia Pastoreková. Duration: 2018-2021.
Projects of The Ministry of Health of the Slovak Republic:
Clinical evaluation of prognostic and predictive value of tissue and serum Carbonic Anhydrase IX in breast cancer. Project code: MZ SR 2019/26-LFUK-14. PI: Faculty of Medicine, Comenius University, Bratislava. PI: Kamil Pohlodek; Cooperating organization: BMC SAV, PI: Ingeborg Režuchová. Duration: 2019/2021.
European Union Structural Funds projects:
Integrative strategy in development of personalized medicine of selected malignant tumours and its impact on quality of life (LISPER). Project code: 313011V446, PI: Lekárska fakulta, UK BA, PI: Lukáš Plank; Cooperating organization: BMC SAV, PI: Miroslav Chovanec. Duration: 2019-2021.
Long-term strategic research of prevention, intervention and mechanisms of obesity and its comorbidities. Project code: NFP313010V344, PI: BMC SAV, PI: Silvia Pastoreková. Duration: 2020-2023.
Selected previous projects:
Biochips and biosensors for glycorecognition, their development, preparation and application in cancer research. Project code: APVV-14-0753. Coordinator: Institute of Chemistry, PI: Jaroslav Katrlík. Partner organization: Biomedical Research Center SAS, PI: Eliška Švastova. Duration: 2015-2019.
Role of the CA IX ectodomain in tumor growth and metastasis. Project code: Leona Lauder and George Schwab Foundation. PI: Silvia Pastoreková. Duration: 2014-2019.
Elucidation of novel pro-metastatic functions of hypoxia-induced carbonic anhydrase IX in pancreatic cancer. Slovak Academic Information Agency (SAIA)—Action Austria—Slovakia. Coordinator: BRC SAS, PI: Eliška Švastova. Host institution: Medical University of Vienna, Institute of Cancer Research, Supervisor: Paola Martinelli. Duration: 02/2018 – 07/2018.
Targeting carbonic anhydrase IX and pyruvate dehydrogenase kinase 1 in hypoxic colorectal tumors. Project code: SASPRO-0035/01/02, PI: Tereza Goliaš. Duration: 2015-2018.
Association of the hypoxia-induced carbonic anhydrase IX with drug response, miRNA profile and oncogenic pathways: from integrative analysis of the NCI60 cancer cell panel to cancer patients. Project code: SAS-MOST-JRP 2014/10. PI: Silvia Pastoreková. Duration: 2015-2017.
Biomedical engineering for cancer and brain disease diagnosis and therapy development. Project code: FP7-PEOPLE-2010-ITN-264417 (Project of the 7th Framework Program of the EU). Coordinator: Michiel J Vellekoop, Vienna University of Technology; Partner Organization: Institute of Virology, SAS, PI: Silvia Pastoreková. Duration: 2011-2015.
Metastatic tumour facilitated by hypoxic tumour microenvironments (METOXIA). Project code: HEALTH-2007-222741 (Project of the 7th Framework Program of the EU). Coordinator: Erik O. Pettersen, University of Oslo; Partner Organization: Institute of Virology, SAS, PI: Silvia Pastoreková. Duration: 2009-2014.
Hypoxia sensing, signalling and adaptation. Project code: COST Action TD0901. Coordinator: Roland Wenger, University of Zurich; Partner organization: Institute of Virology, SAS, PI: Silvia Pastoreková. Duration: 2009-2013.